Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
European Low- and Intermediate-Risk Neuroblastoma
2010-021396-81Phase 3Active
- Sponsor
- Health Research Institute Hospital La Fe
- Start
- Nov 2011
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of carboplatin, cyclophosphamide, doxorubicin, etoposide, vincristine and 1 more in neuroblastoma (3 arms), sponsored by Health Research Institute Hospital La Fe. Primary endpoint: Time to initiation of carboplatin and etoposide during the first year after diagnosis. Started Nov 2011; status: active.
02
Drugs
carboplatincyclophosphamidedoxorubicinetoposidevincristine
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2010-021396-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021396-81.